Transcatheter heart valve therapies for all heart valves: from an innovation strategy to mainstream therapy
Chairpersons: M.B. Leon , S. Windecker
Objectives:
To learn about the Edwards Lifesciences innovation pipeline for the aortic, mitral, tricuspid and pulmonary valveTo understand the latest and upcoming evidence in the aortic field
To learn about the economic value of innovative technology
Lectures
Session objectives
S. Windecker
The aortic valve: standard of care for intermediate-risk, high-risk and inoperable patients; expanded indication studies underway
B. Prendergast
What is the value of innovation in less invasive procedures to patients and healthcare systems?
M. Ayling
TAVI optimisation with the Edwards SAPIEN 3 Valve – "7 Cases in a day" - Recorded case from Leiden University Medical Center - Leiden, The Netherlands
F. van der Kley